Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

NovoCure Limited - Ordinary Shares (NQ:NVCR)

17.38 -0.06 (-0.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Why NovoCure Stock Skyrocketed This Week
Via The Motley Fool
Topics Earnings Stocks
Exposures Financial US Equities
Why NovoCure Stock Leaped 4% Higher Today
Via The Motley Fool
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs. 
Via Benzinga
Topics World Trade
Exposures Tariff
NovoCure Surpasses Q1 Expectations
NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Earnings Scheduled For April 24, 2025
Via Benzinga
NovoCure's Earnings: A Preview
Via Benzinga
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
Via The Motley Fool
Why NovoCure Stock Was Withering on Wednesday
Via The Motley Fool
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
NVCR earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025
NovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion. 
Via Benzinga
NovoCure Q4 EPS Misses, Revenue Matches
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
Via The Motley Fool
Earnings Scheduled For February 27, 2025
Via Benzinga
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business." 
Via Benzinga
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Why NovoCure Stock Was Winning Big This Week
Via The Motley Fool
Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds
The company is soon to seek regulatory approval in the U.S. and abroad. 
Via Investor's Business Daily
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN. 
Via Benzinga
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks. 
Via Benzinga
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Navigating 5 Analyst Ratings For NovoCure
Via Benzinga
Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Via Benzinga
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients. 
Via Benzinga
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
NovoCure (NVCR) Q3 2024 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips
U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.